-
2
-
-
0028024881
-
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo
-
Aukrust P., Froland S.S., Liabakk N.B., Muller F., Nordoy I., Haug C., Espevik T. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994, 84:2136-2143.
-
(1994)
Blood
, vol.84
, pp. 2136-2143
-
-
Aukrust, P.1
Froland, S.S.2
Liabakk, N.B.3
Muller, F.4
Nordoy, I.5
Haug, C.6
Espevik, T.7
-
3
-
-
0028113940
-
High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
-
Basta M., Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 1994, 94:1729-1735.
-
(1994)
J. Clin. Invest.
, vol.94
, pp. 1729-1735
-
-
Basta, M.1
Dalakas, M.C.2
-
4
-
-
10744224652
-
F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins
-
Basta M., Van G.F., Luccioli S., Billings E.M., Vortmeyer A.O., Baranyi L., Szebeni J., Alving C.R., Carroll M.C., Berkower I., Stojilkovic S.S., Metcalfe D.D. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 2003, 9:431-438.
-
(2003)
Nat. Med.
, vol.9
, pp. 431-438
-
-
Basta, M.1
Van, G.F.2
Luccioli, S.3
Billings, E.M.4
Vortmeyer, A.O.5
Baranyi, L.6
Szebeni, J.7
Alving, C.R.8
Carroll, M.C.9
Berkower, I.10
Stojilkovic, S.S.11
Metcalfe, D.D.12
-
5
-
-
0037438669
-
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin
-
Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., Chevailler A., Mouthon L., Weill B., Bruneval P., Kazatchkine M.D., Kaveri S.V. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003, 101:758-765.
-
(2003)
Blood
, vol.101
, pp. 758-765
-
-
Bayry, J.1
Lacroix-Desmazes, S.2
Carbonneil, C.3
Misra, N.4
Donkova, V.5
Pashov, A.6
Chevailler, A.7
Mouthon, L.8
Weill, B.9
Bruneval, P.10
Kazatchkine, M.D.11
Kaveri, S.V.12
-
6
-
-
84858615495
-
Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis
-
Berlot G., et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J. Crit. Care 2012, 27:167-171.
-
(2012)
J. Crit. Care
, vol.27
, pp. 167-171
-
-
Berlot, G.1
-
7
-
-
33646444174
-
Do plasma substitutes have additional properties beyond correcting volume deficits?
-
Boldt J. Do plasma substitutes have additional properties beyond correcting volume deficits?. Shock 2006, 25:103-116.
-
(2006)
Shock
, vol.25
, pp. 103-116
-
-
Boldt, J.1
-
8
-
-
44849139178
-
New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs
-
Castellheim A., Thorgersen E.B., Hellerud B.C., Pharo A., Johansen H.T., Brosstad F., Gaustad P., Brun H., Fosse E., Tonnessen T.I., Nielsen E.W., Mollnes T.E. New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs. Scand. J. Immunol. 2008, 68:75-84.
-
(2008)
Scand. J. Immunol.
, vol.68
, pp. 75-84
-
-
Castellheim, A.1
Thorgersen, E.B.2
Hellerud, B.C.3
Pharo, A.4
Johansen, H.T.5
Brosstad, F.6
Gaustad, P.7
Brun, H.8
Fosse, E.9
Tonnessen, T.I.10
Nielsen, E.W.11
Mollnes, T.E.12
-
9
-
-
38349058657
-
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock
-
Dellinger R.P., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2008, 34:17-60.
-
(2008)
Intensive Care Med.
, vol.34
, pp. 17-60
-
-
Dellinger, R.P.1
-
10
-
-
72149125317
-
Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology
-
Hartung H.P., Mouthon L., Ahmed R., Jordan S., Laupland K.B., Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin. Exp. Immunol. 2009, 158(Suppl 1):23-33.
-
(2009)
Clin. Exp. Immunol.
, vol.158
, Issue.SUPPL 1
, pp. 23-33
-
-
Hartung, H.P.1
Mouthon, L.2
Ahmed, R.3
Jordan, S.4
Laupland, K.B.5
Jolles, S.6
-
11
-
-
0034031005
-
Release of Gram-negative outer-membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5
-
Hellman J., Loiselle P.M., Zanzot E.M., Allaire J.E., Tehan M.M., Boyle L.A., Kurnick J.T., Warren H.S. Release of Gram-negative outer-membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5. J. Infect. Dis. 2000, 181:1034-1043.
-
(2000)
J. Infect. Dis.
, vol.181
, pp. 1034-1043
-
-
Hellman, J.1
Loiselle, P.M.2
Zanzot, E.M.3
Allaire, J.E.4
Tehan, M.M.5
Boyle, L.A.6
Kurnick, J.T.7
Warren, H.S.8
-
12
-
-
37549057568
-
Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia
-
Hoffman J.N., Fertmann J.M., Vollmar B., Laschke M.W., Jauch K.W., Menger M.D. Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia. Shock 2008, 29:133-139.
-
(2008)
Shock
, vol.29
, pp. 133-139
-
-
Hoffman, J.N.1
Fertmann, J.M.2
Vollmar, B.3
Laschke, M.W.4
Jauch, K.W.5
Menger, M.D.6
-
13
-
-
80052175401
-
Intracellular sensing of microbes and danger signals by the inflammasomes
-
Horvath G.L., Schrum J.E., De Nardo C.M., Latz E. Intracellular sensing of microbes and danger signals by the inflammasomes. Immunol. Rev. 2011, 243:119-135.
-
(2011)
Immunol. Rev.
, vol.243
, pp. 119-135
-
-
Horvath, G.L.1
Schrum, J.E.2
De Nardo, C.M.3
Latz, E.4
-
14
-
-
0027242370
-
Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation
-
Jackson S.K., Parton J., Barnes R.A., Poynton C.H., Fegan C. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur. J. Clin. Invest. 1993, 23:540-545.
-
(1993)
Eur. J. Clin. Invest.
, vol.23
, pp. 540-545
-
-
Jackson, S.K.1
Parton, J.2
Barnes, R.A.3
Poynton, C.H.4
Fegan, C.5
-
15
-
-
0035818044
-
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin
-
Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 2001, 345:747-755.
-
(2001)
N. Engl. J. Med.
, vol.345
, pp. 747-755
-
-
Kazatchkine, M.D.1
Kaveri, S.V.2
-
16
-
-
36448938357
-
Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock
-
Kreymann K.G., de H.G., Nierhaus A., Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit. Care Med. 2007, 35:2677-2685.
-
(2007)
Crit. Care Med.
, vol.35
, pp. 2677-2685
-
-
Kreymann, K.G.1
de, H.G.2
Nierhaus, A.3
Kluge, S.4
-
17
-
-
0032586346
-
Efficacy and potential clinical applications of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion
-
Lissner R., Struff W.G., Autenrieth I.B., Woodcock B.G., Karch H. Efficacy and potential clinical applications of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion. Eur. J. Surg. Suppl. 1999, 17-25.
-
(1999)
Eur. J. Surg. Suppl.
, pp. 17-25
-
-
Lissner, R.1
Struff, W.G.2
Autenrieth, I.B.3
Woodcock, B.G.4
Karch, H.5
-
18
-
-
33644640503
-
Preclinical models of shock and sepsis: what can they tell us?
-
Marshall J.C., Deitch E., Moldawer L.L., Opal S., Redl H., van der Poll T. Preclinical models of shock and sepsis: what can they tell us?. Shock 2005, 24(Suppl. 1):1-6.
-
(2005)
Shock
, vol.24
, Issue.SUPPL. 1
, pp. 1-6
-
-
Marshall, J.C.1
Deitch, E.2
Moldawer, L.L.3
Opal, S.4
Redl, H.5
van der Poll, T.6
-
19
-
-
0036721025
-
Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation
-
Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., Lambris J.D. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002, 100:1869-1877.
-
(2002)
Blood
, vol.100
, pp. 1869-1877
-
-
Mollnes, T.E.1
Brekke, O.L.2
Fung, M.3
Fure, H.4
Christiansen, D.5
Bergseth, G.6
Videm, V.7
Lappegard, K.T.8
Kohl, J.9
Lambris, J.D.10
-
20
-
-
0028928224
-
Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties
-
Mollnes T.E., Hogasen K., Hoaas B.F., Michaelsen T.E., Garred P., Harboe M. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand. J. Immunol. 1995, 41:449-456.
-
(1995)
Scand. J. Immunol.
, vol.41
, pp. 449-456
-
-
Mollnes, T.E.1
Hogasen, K.2
Hoaas, B.F.3
Michaelsen, T.E.4
Garred, P.5
Harboe, M.6
-
21
-
-
0029920574
-
Mechanisms of action of intravenous immune globulin in immune-mediated diseases
-
Mouthon L., Kaveri S.V., Spalter S.H., Lacroix-Desmazes S., Lefranc C., Desai R., Kazatchkine M.D. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin. Exp. Immunol. 1996, 104(Suppl. 1):3-9.
-
(1996)
Clin. Exp. Immunol.
, vol.104
, Issue.SUPPL. 1
, pp. 3-9
-
-
Mouthon, L.1
Kaveri, S.V.2
Spalter, S.H.3
Lacroix-Desmazes, S.4
Lefranc, C.5
Desai, R.6
Kazatchkine, M.D.7
-
22
-
-
42649089750
-
Anti-inflammatory actions of intravenous immunoglobulin
-
Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 2008, 26:513-533.
-
(2008)
Annu. Rev. Immunol.
, vol.26
, pp. 513-533
-
-
Nimmerjahn, F.1
Ravetch, J.V.2
-
23
-
-
79953285696
-
Colloids versus crystalloids for fluid resuscitation in critically ill patients
-
Perel P., Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst. Rev. 2011, CD000567.
-
(2011)
Cochrane Database Syst. Rev.
-
-
Perel, P.1
Roberts, I.2
-
24
-
-
34250890817
-
Pathophysiology of sepsis
-
Remick D.G. Pathophysiology of sepsis. Am. J. Pathol. 2007, 170:1435-1444.
-
(2007)
Am. J. Pathol.
, vol.170
, pp. 1435-1444
-
-
Remick, D.G.1
-
25
-
-
0032938501
-
Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation
-
Rieben R., Roos A., Muizert Y., Tinguely C., Gerritsen A.F., Daha M.R. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999, 93:942-951.
-
(1999)
Blood
, vol.93
, pp. 942-951
-
-
Rieben, R.1
Roos, A.2
Muizert, Y.3
Tinguely, C.4
Gerritsen, A.F.5
Daha, M.R.6
-
26
-
-
0035829842
-
Early goal-directed therapy in the treatment of severe sepsis and septic shock
-
Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001, 345:1368-1377.
-
(2001)
N. Engl. J. Med.
, vol.345
, pp. 1368-1377
-
-
Rivers, E.1
Nguyen, B.2
Havstad, S.3
Ressler, J.4
Muzzin, A.5
Knoblich, B.6
Peterson, E.7
Tomlanovich, M.8
-
27
-
-
0033855231
-
Systemic activation of coagulation and fibrynolysis in a porcine model of serogroup A streptococcal shock
-
Saetre T., Lindgaard A.K., Lyberg T. Systemic activation of coagulation and fibrynolysis in a porcine model of serogroup A streptococcal shock. Blood Coagul. Fibrinolysis 2000, 11:433-438.
-
(2000)
Blood Coagul. Fibrinolysis
, vol.11
, pp. 433-438
-
-
Saetre, T.1
Lindgaard, A.K.2
Lyberg, T.3
-
28
-
-
84858394440
-
Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective
-
Shankar-Hari M., Spencer J., Sewell W.A., Rowan K.M., Singer M. Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit. Care 2012, 16:206.
-
(2012)
Crit. Care
, vol.16
, pp. 206
-
-
Shankar-Hari, M.1
Spencer, J.2
Sewell, W.A.3
Rowan, K.M.4
Singer, M.5
-
29
-
-
38349166112
-
Effects of IGM-enriched solution on polymorphonuclear neutrophil function, bacterial clearance, and lung histology in endotoxemia
-
Stehr S.N., Knels L., Weissflog C., Schober J., Haufe D., Lupp A., Koch T., Heller A.R. Effects of IGM-enriched solution on polymorphonuclear neutrophil function, bacterial clearance, and lung histology in endotoxemia. Shock 2008, 29:167-172.
-
(2008)
Shock
, vol.29
, pp. 167-172
-
-
Stehr, S.N.1
Knels, L.2
Weissflog, C.3
Schober, J.4
Haufe, D.5
Lupp, A.6
Koch, T.7
Heller, A.R.8
-
30
-
-
77952296285
-
CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs
-
Thorgersen E.B., Hellerud B.C., Nielsen E.W., Barratt-Due A., Fure H., Lindstad J.K., Pharo A., Fosse E., Tonnessen T.I., Johansen H.T., Castellheim A., Mollnes T.E. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J. 2010, 24:712-722.
-
(2010)
FASEB J.
, vol.24
, pp. 712-722
-
-
Thorgersen, E.B.1
Hellerud, B.C.2
Nielsen, E.W.3
Barratt-Due, A.4
Fure, H.5
Lindstad, J.K.6
Pharo, A.7
Fosse, E.8
Tonnessen, T.I.9
Johansen, H.T.10
Castellheim, A.11
Mollnes, T.E.12
-
31
-
-
0031929252
-
Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product
-
Trautmann M., Held T.K., Susa M., Karajan M.A., Wulf A., Cross A.S., Marre R. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin. Exp. Immunol. 1998, 111:81-90.
-
(1998)
Clin. Exp. Immunol.
, vol.111
, pp. 81-90
-
-
Trautmann, M.1
Held, T.K.2
Susa, M.3
Karajan, M.A.4
Wulf, A.5
Cross, A.S.6
Marre, R.7
-
32
-
-
0036336714
-
The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]
-
Tugrul S., Ozcan P.E., Akinci O., Seyhun Y., Cagatay A., Cakar N., Esen F. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit. Care 2002, 6:357-362.
-
(2002)
Crit. Care
, vol.6
, pp. 357-362
-
-
Tugrul, S.1
Ozcan, P.E.2
Akinci, O.3
Seyhun, Y.4
Cagatay, A.5
Cakar, N.6
Esen, F.7
-
33
-
-
0015342397
-
Evaluation of hemoconcentration from hematocrit measurements
-
Van B.W. Evaluation of hemoconcentration from hematocrit measurements. J. Appl. Physiol. 1972, 32:712-713.
-
(1972)
J. Appl. Physiol.
, vol.32
, pp. 712-713
-
-
Van, B.W.1
-
34
-
-
0035169276
-
Intravenous immunoglobulin for prophylaxis and therapy of sepsis
-
Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr. Opin. Crit. Care 2001, 7:354-361.
-
(2001)
Curr. Opin. Crit. Care
, vol.7
, pp. 354-361
-
-
Werdan, K.1
-
35
-
-
0019906260
-
Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli
-
Ziegler E.J., McCutchan J.A., Fierer J., Glauser M.P., Sadoff J.C., Douglas H., Braude A.I. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 1982, 307:1225-1230.
-
(1982)
N. Engl. J. Med.
, vol.307
, pp. 1225-1230
-
-
Ziegler, E.J.1
McCutchan, J.A.2
Fierer, J.3
Glauser, M.P.4
Sadoff, J.C.5
Douglas, H.6
Braude, A.I.7
|